Post-marketing survey Evaluating the Safety and Efficacy of Japanese cedar pollen sublingual immunotherapy tablet (Stratified analysis by with or without asthma, 2018 to 2020)

Abstract

The Japanese cedar pollen (JCP) sublingual immunotherapy (SLIT) tablet (5,000 JAU Torii, Japan/ALK, Denmark) has been available for Japanese cedar pollinosis in Japan since 2018. Post-marketing surveillance of the JCP SLIT tablets has been initiated to investigate the safety and efficacy during two seasons.